Pharmacologists have been waging an ongoing battle to overcome infectious microbes' resistance to lifesaving drugs.
In Sanders' signature "Medicare for All" bill, drug prices would be essentially set by the secretary of health and human services.
Once Medicare for All empowers the secretary to decide the appropriate revenue for a drug company, what will happen to that $121 billion of research investment?
The rule introduces add-on payment pathways for newly developed antibiotics that are designated "Qualified infectious disease products" by the Food and Drug Administration.
In general, new drugs are granted periods of exclusivity by the FDA that are separate from patent protections, lasting from three to seven years depending on the drug.
In addition to offering greater protections for new drugs, the rule also increases the add-on payment from 50% of costs to 75% for qualified infectious disease products, and it considers them new products rather than improved products, which would eliminate the need to show "Substantial clinical improvement" over an existing drug.
Rather than imposing strict regulations from a federal office onto firms and how they operate their businesses, the Centers for Medicare and Medicaid Services is leveraging the substantial medical and pharmaceutical industry to tackle an impending health crisis.
https://www.dailysignal.com/2019/09/23/how-medicare-for-all-could-block-medical-progress/
In Sanders' signature "Medicare for All" bill, drug prices would be essentially set by the secretary of health and human services.
Once Medicare for All empowers the secretary to decide the appropriate revenue for a drug company, what will happen to that $121 billion of research investment?
The rule introduces add-on payment pathways for newly developed antibiotics that are designated "Qualified infectious disease products" by the Food and Drug Administration.
In general, new drugs are granted periods of exclusivity by the FDA that are separate from patent protections, lasting from three to seven years depending on the drug.
In addition to offering greater protections for new drugs, the rule also increases the add-on payment from 50% of costs to 75% for qualified infectious disease products, and it considers them new products rather than improved products, which would eliminate the need to show "Substantial clinical improvement" over an existing drug.
Rather than imposing strict regulations from a federal office onto firms and how they operate their businesses, the Centers for Medicare and Medicaid Services is leveraging the substantial medical and pharmaceutical industry to tackle an impending health crisis.
https://www.dailysignal.com/2019/09/23/how-medicare-for-all-could-block-medical-progress/
No comments:
Post a Comment